113 related articles for article (PubMed ID: 1903579)
1. Possible mechanism of vascular reocclusion after initially successful thrombolysis with recombinant tissue-type plasminogen activator.
Yamada Y; Furui H; Furumichi T; Yamauchi K; Yokota M; Saito H
Am Heart J; 1991 Jun; 121(6 Pt 1):1618-27. PubMed ID: 1903579
[TBL] [Abstract][Full Text] [Related]
2. Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo.
Fitzgerald DJ; Wright F; FitzGerald GA
Circ Res; 1989 Jul; 65(1):83-94. PubMed ID: 2500270
[TBL] [Abstract][Full Text] [Related]
3. Effects of streptokinase, urokinase, and recombinant tissue plasminogen activator on platelet aggregability and stability of platelet aggregates.
Terres W; Umnus S; Mathey DG; Bleifeld W
Cardiovasc Res; 1990 Jun; 24(6):471-7. PubMed ID: 2167173
[TBL] [Abstract][Full Text] [Related]
4. Coronary arterial thrombolysis with low-dose synergistic combinations of recombinant tissue-type plasminogen activator (rt-PA) and recombinant single-chain urokinase-type plasminogen activator (rscu-PA) for acute myocardial infarction.
Collen D; Van de Werf F
Am J Cardiol; 1987 Sep; 60(7):431-4. PubMed ID: 3115077
[TBL] [Abstract][Full Text] [Related]
5. Mediation of reocclusion by thromboxane A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis.
Golino P; Ashton JH; Glas-Greenwalt P; McNatt J; Buja LM; Willerson JT
Circulation; 1988 Mar; 77(3):678-84. PubMed ID: 3124975
[TBL] [Abstract][Full Text] [Related]
6. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction.
Nordt TK; Moser M; Kohler B; Ruef J; Peter K; Kübler W; Bode C
Thromb Haemost; 1998 Dec; 80(6):881-6. PubMed ID: 9869154
[TBL] [Abstract][Full Text] [Related]
7. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
Yao SK; Ober JC; Ferguson JJ; Anderson HV; Maraganore J; Buja LM; Willerson JT
Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
[TBL] [Abstract][Full Text] [Related]
8. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
Haskel EJ; Prager NA; Sobel BE; Abendschein DR
Circulation; 1991 Mar; 83(3):1048-56. PubMed ID: 1900222
[TBL] [Abstract][Full Text] [Related]
9. [Coronary thrombolysis by t-PA and pro-UK].
Kanmatsuse K; Suzuki T; Kajiwara N
Nihon Rinsho; 1989 Apr; 47(4):910-6. PubMed ID: 2501541
[No Abstract] [Full Text] [Related]
10. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
Golino P; Ashton JH; McNatt J; Glas-Greenwalt P; Yao SK; O'Brien RA; Buja LM; Willerson JT
Circulation; 1989 Apr; 79(4):911-9. PubMed ID: 2494005
[TBL] [Abstract][Full Text] [Related]
11. Experiences with pro-urokinase and potentiation of its fibrinolytic effect by urokinase and by tissue plasminogen activator.
Gurewich V
J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):16B-21B. PubMed ID: 3117859
[TBL] [Abstract][Full Text] [Related]
12. Coronary thrombolysis with clot-selective plasminogen activators.
Collen D; Bounameaux H
Herz; 1986 Feb; 11(1):9-15. PubMed ID: 3082731
[TBL] [Abstract][Full Text] [Related]
13. [New thrombolytic agents in myocardial infarction].
Charbonnier B; Lang M; Brochier M
Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
[TBL] [Abstract][Full Text] [Related]
14. The thrombolytic effects of native tissue-type plasminogen activator (AK-124) on experimental canine coronary thrombosis.
Tomaru T; Uchida Y; Sonoki H; Tsukamoto M; Sugimoto T
Angiology; 1989 May; 40(5):429-35. PubMed ID: 2495745
[TBL] [Abstract][Full Text] [Related]
15. Systemic lysis protects against the effects of platelet activation during coronary thrombolysis.
Fitzgerald DJ; Hanson M; FitzGerald GA
J Clin Invest; 1991 Nov; 88(5):1589-95. PubMed ID: 1939647
[TBL] [Abstract][Full Text] [Related]
16. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
Takiguchi Y; Asai F; Wada K; Nakashima M
Thromb Haemost; 1995 Apr; 73(4):683-8. PubMed ID: 7495079
[TBL] [Abstract][Full Text] [Related]
17. Intravenous thrombolytic therapy with a combination of single-chain urokinase-type plasminogen activator and recombinant tissue-type plasminogen activator in acute myocardial infarction.
Bode C; Schuler G; Nordt T; Schönermark S; Baumann H; Richardt G; Dietz R; Gurewich V; Kübler W
Circulation; 1990 Mar; 81(3):907-13. PubMed ID: 2106403
[TBL] [Abstract][Full Text] [Related]
18. Aggregation of washed platelets by plasminogen and plasminogen activators is mediated by plasmin and is inhibited by a synthetic peptide disulfide.
Puri RN; Hu CJ; Matsueda R; Umeyama H; Colman RW
Thromb Res; 1992 Mar; 65(4-5):533-47. PubMed ID: 1535463
[TBL] [Abstract][Full Text] [Related]
19. Tissue-type plasminogen activator inhibits aggregation of platelets in vitro.
Mizuta T; Imai C
Life Sci; 1988; 43(12):955-63. PubMed ID: 3139948
[TBL] [Abstract][Full Text] [Related]
20. New developments in thrombolytic therapy.
Collen D; Gold HK
Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]